US Bancorp’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

US Bancorp’s Portfolio GEVA Stock Details GEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-1,131	Closed	-$110K	–	3735
2015 Q1	$110K	Sell	1,131 -68	-6%	-$7.2K	﹤0.01%	2117
2014 Q4	$112K	Buy	1,199 +262	+28%	+$20.7K	﹤0.01%	2077
2014 Q3	$65K	Buy	937 +66	+8%	+$4.73K	﹤0.01%	2357
2014 Q2	$91K	Buy	+871	New	+$74.1K	﹤0.01%	2179

US Bancorp's GEVA Position: Q2 2015 in Review

US Bancorp sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 1,131 shares — an estimated $110K sold.

US Bancorp first reported a position in GEVA in Q2 2014 and held it in 4 quarters. The position peaked at $112K in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

US Bancorp reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
US Bancorp sold 1,131 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $110K.
US Bancorp first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2014 and held it in 4 quarters.
US Bancorp's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $112K in Q4 2014.
0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on US Bancorp's 13F filing for Q2 2015, filed 10 Aug 2015.